Compare HLI & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLI | SYRE |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.5B |
| IPO Year | 2015 | 2015 |
| Metric | HLI | SYRE |
|---|---|---|
| Price | $124.95 | $102.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $194.29 | $85.08 |
| AVG Volume (30 Days) | 942.1K | ★ 942.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 6.87 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $2,617,516,000.00 | N/A |
| Revenue This Year | $13.77 | N/A |
| Revenue Next Year | $12.10 | N/A |
| P/E Ratio | $107.09 | ★ N/A |
| Revenue Growth | ★ 9.55 | N/A |
| 52 Week Low | $112.83 | $14.51 |
| 52 Week High | $211.78 | $108.14 |
| Indicator | HLI | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 55.31 |
| Support Level | $112.83 | $92.37 |
| Resistance Level | $144.92 | $104.07 |
| Average True Range (ATR) | 5.29 | 5.63 |
| MACD | -0.97 | -0.22 |
| Stochastic Oscillator | 38.13 | 63.06 |
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.